Halozyme Therapeutics, Inc. (HALO) Given a $20.00 Price Target at Piper Jaffray Companies
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned a $20.00 price objective by investment analysts at Piper Jaffray Companies in a research report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 58.10% from the company’s previous close.
Several other equities research analysts also recently weighed in on the stock. Jefferies Group LLC reaffirmed an “underperform” rating and set a $7.00 target price (up from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday. Canaccord Genuity set a $16.00 target price on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 26th. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 1st. Barclays PLC reaffirmed an “overweight” rating and set a $16.00 target price on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. Finally, ValuEngine raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $14.88.
Shares of Halozyme Therapeutics (NASDAQ HALO) traded down 1.82% during trading on Thursday, hitting $12.42. 40,003 shares of the stock were exchanged. Halozyme Therapeutics has a one year low of $8.18 and a one year high of $15.20. The company’s market cap is $1.76 billion. The stock’s 50 day moving average price is $13.28 and its 200-day moving average price is $13.12.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to analyst estimates of $31.76 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The business’s revenue was up 1.2% compared to the same quarter last year. On average, analysts predict that Halozyme Therapeutics will post ($0.97) EPS for the current year.
Several large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth approximately $122,000. Teacher Retirement System of Texas bought a new position in Halozyme Therapeutics during the second quarter worth approximately $129,000. Prudential Financial Inc. increased its position in Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 940 shares during the period. Stifel Financial Corp bought a new position in Halozyme Therapeutics during the first quarter worth approximately $187,000. Finally, Karp Capital Management Corp bought a new position in Halozyme Therapeutics during the first quarter worth approximately $188,000. 81.49% of the stock is currently owned by institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.